The one-month return of Third Harmonic Bio, Inc. (NASDAQ:THRD) was 48.28%, and its shares lost 55.90% of their value over the last 52 weeks. On May 1, 2025, Third Harmonic Bio, Inc. (NASDAQ:THRD ...

U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with resu ...

SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today ...

Third Harmonic Bio shares were up 39%, trading around $5.06 at the time of publication Monday, according to Benzinga Pro. Read Next: S&P 500 Could Tank To 4,000 If ‘Trump Put’ Fizzles, Says ...

Third Harmonic Bio's only asset failed in a phase 1 safety trial, which paralyzes its clinical pipeline. Find out why I rate THRD stock a Sell.

Third Harmonic Bio, which emerged from stealth early this year with a lead drug from Novartis and a $105 million round of funding, has not yet set any financial terms for its planned IPO.

THIRD HARMONIC BIO posted quarterly earnings results on Thursday, May 8th.The company reported earnings of -$0.35 per share, missing estimates of -$0.30 by $0.05. The company also reported revenue ...

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases ...

Third Harmonic Bio reported a $29.6 million loss in 2021 and a loss of $12.8 million in 2020, with no revenue yet generated. Clinical stage biopharmaceutical company Third Harmonic Bio Inc. on ...

Third Harmonic Bio, Inc. (NASDAQ:THRD) is a biopharmaceutical company. The one-month return of Third Harmonic Bio, Inc. (NASDAQ:THRD) was 48.28%, and its shares lost 55.90% of their value over the ...